FRESENIUS BREAKTHROUGH OF THE YEAR YOUNG INVESTIGATOR AWARD

This award is generously supported by the Fresenius Foundation in 2025, 2026 & 2027, it recognises the breakthrough of the year in the gene and cell therapy field and the impact of research carried out by early career researchers (Under 40). The awardee will present a talk at the ESGCT Annual Congress.

Nerea Zabaleta Fresenius Breakthrough of the year Young Investigator Award in 2025

Eligibility Criteria

1. Nominees must be a member of the ESGCT

2. All young investigators under 40 years old

3. Extension of this period may be allowed in case of eligible career breaks: maternity or paternity leave (1 year per child born after the PhD award); leave taken for long-term illness or national service; leave taken for unavoidable statutory reasons (e.g. clinical qualification). The cumulative eligibility period should not surpass 5 years following the award of the first PhD, unless the Board agrees they are the best candidate for the award.

4. For medical doctors, date of the clinical speciality completion is the time reference for calculation of the eligibility time-window. For MD and PhD, date of the PhD award takes precedence in the calculation of the eligibility time-window.

5. Winner must submit an abstract to the ESGCT congress

   
   

Nomination and Selection Process

Applicants must have submitted an abstract to the ESGCT congress.  The winner of this award will be one of the highest scoring abstracts which the scientific committee considers as being the breakthrough of the year.

AWARD VALUE: €3000

Fresenius breakthrough of the year young investigator award winners

2025 - Nerea Zabaleta